Inventiva (IVA) Granted FDA's Fast Track Designation of lanifibranorin NASH Encompasses the Treatment of NASH with Compensated Cirrhosis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. CRWV

Go back to Inventiva (IVA) Granted FDA's Fast Track Designation of lanifibranorin NASH Encompasses the Treatment of NASH with Compensated Cirrhosis

Inventiva (IVA) Reports Q2 Loss of EUR0.60

September 20, 2021 4:13 PM EDT

Inventiva (NASDAQ: IVA) reported Q2 EPS of (EUR0.60). Revenue for the quarter came in at EUR139 thousand.

For earnings history and earnings-related data on Inventiva (IVA) click here.

... More